BioSpace - Print News Article

Cortex Biochem, Inc. And Bouty S.p.A. Sign Exclusive Distribution Agreement; Bouty To Market Cortex Biochem Inc.'s MagaZorb Nucleic Acid Isolation Kits In Italy 10/19/2005 5:08:54 PM RALEIGH, N.C.--(BUSINESS WIRE)--June 14, 2005--Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, has established an exclusive distribution and limited license agreement with Bouty S.p.A. of Milan, Italy. Effective January of this year, the agreement allows Bouty and Bouty's subsidiary Biotechnology Division, Technogenetics S.r.l., to promote, market and sell Cortex Biochem(TM) Inc.'s MagaZorb(R) Nucleic Acid Isolation Kits and associated reagents in Italy. "We are very excited about our agreement with Bouty, which launches our selling efforts of MagaZorb(R) in Europe," said Matt Pourfarzaneh, President and CEO of Cortex Biochem(TM) Inc. "We are confident that this is the ideal partnership to firmly establish our technology in the European market. We anticipate progressive market penetration since MagaZorb(R) provides greater value with better performing, faster, flexible nucleic acid isolation.

Cortex Biochem, Inc. And Bouty S.p.A. Sign Exclusive Distribution Agreement; Bouty To Market Cortex Biochem Inc.'s MagaZorb Nucleic Acid Isolation Kits In Italy
10/19/2005 5:08:54 PM

RALEIGH, N.C.--(BUSINESS WIRE)--June 14, 2005--Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, has established an exclusive distribution and limited license agreement with Bouty S.p.A. of Milan, Italy. Effective January of this year, the agreement allows Bouty and Bouty's subsidiary Biotechnology Division, Technogenetics S.r.l., to promote, market and sell Cortex Biochem(TM) Inc.'s MagaZorb(R) Nucleic Acid Isolation Kits and associated reagents in Italy. "We are very excited about our agreement with Bouty, which launches our selling efforts of MagaZorb(R) in Europe," said Matt Pourfarzaneh, President and CEO of Cortex Biochem(TM) Inc. "We are confident that this is the ideal partnership to firmly establish our technology in the European market. We anticipate progressive market penetration since MagaZorb(R) provides greater value with better performing, faster, flexible nucleic acid isolation.